6 completed, 2 withdrawn, 1 recruiting, 1 unknown. 10 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow testosterone enanthate: new trials by email Literature Review of testosterone enanthate trials Research Report on testosterone enanthate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-11-06 |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Testosterone Effects on Pelvic Floor Muscles Testosterone Enanthate, Placebo - Urinary Incontinence, Menopause | Phase 3 | Withdrawn | Brigham and Women's Hospital | 2021-01-01 | 2022-07-20 | |
| Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 133 | 2015-07-01 | 2018-03-30 |
| Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 3 | Completed | Antares Pharma Inc. | 150 | 2014-07-01 | 2018-02-07 |
| Testosterone Administration and ACL Reconstruction in Men Testosterone, Placebo - Muscle Atrophy, ACL Reconstruction | Phase 3 | Completed | University of Southern California | 14 | 2012-04-01 | 2022-03-02 |
| Optimizing Protein Intake in Older Americans With Mobility Limitations Testosterone enanthate - Mobility Limitation | Phase 3 | Completed | Brigham and Women's Hospital | 92 | 2011-05-01 | 2021-07-29 |
| Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients Testosterone, Placebo - Advanced Cancer | Phase 3 | Completed | M.D. Anderson Cancer Center | 53 | 2009-09-01 | 2016-09-13 |
| The Effect of 5-Alpha Reductase on Testosterone in Men testosterone enanthate, duastride - Sex Disorders | Phase 3 | Unknown | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 184 | 2003-08-01 | 2005-11-07 |
| Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency Testosterone Enanthate, Placebo - Men With Low Testosterone Levels | Phase 2 / Phase 3 | Completed | Leonard S. Marks, M.D. | 44 | 2003-04-01 | 2021-04-28 |
Hypogonadism (3) · Eunuchism (1) · Fatigue (1) · Mobility Limitation (1) · Muscular Atrophy (1) · Neoplasms (1) · Osteoarthritis (1) · Pulmonary Disease, Chronic Obstructive (1) · Sexual Dysfunction, Physiological (1) · Urinary Incontinence (1) · Wounds and Injuries (1)
Antares Pharma Inc. (2) · Brigham and Women's Hospital (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Halozyme Therapeutics (1) · Leonard S. Marks, M.D. (1) · M.D. Anderson Cancer Center (1) · The University of Texas Medical Branch, Galveston (1) · University of Southern California (1)
United States (9)
Shalender Bhasin, MD (2) · Gary Bedel, MD (1) · Grace Huang, MD (1) · Jed Kaminetsky, MD (1) · Leonard S Marks, M.D. (1) · Randall J Urban, MD (1) · Rony Dev, DO (1) · Todd Schroeder, PhD (1)
PMID 17105798, PMID 25481088, PMID 28840147, PMID 29188864, PMID 29532075, PMID 30932132, PMID 31551193, PMID 33417663
R01AG037547 (1)